Edotecarin

DB04882InvestigationalSmall molecule

Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.

Mechanism: Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme complex and enhanced single-strand DNA cleavage, resulting in inhibition of DNA replication and decreased tumor cell proliferation.
Curator reviewed
Primary indication: Clinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors.Curator reviewed
Formula / weight: C₂₉H₂₈N₄O₁₁ · 608.56 g/mol (avg)
Code names: J-107088 · PF-804950 · PHA-782615

Resolves to

Compound

UNII1V8X590XDPCAS174402-32-5ChEMBLCHEMBL435191PubChem9808998KEGGD03954

Structure

InChIKeyQMVPQBFHUJZJCS-NTKFZFFISA-NSMILESOCC(CO)NN1C(=O)C2=C3C(NC4=C3C=CC(O)=C4)=C3N([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C4=C(C=CC(O)=C4)C3=C2C1=O

Targets

P11387TOP1

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Edotecarin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account